Research goal
Covers compounds researched for tendon, ligament, and muscle repair; wound healing; angiogenesis; and accelerated recovery from injury or overuse.
| Compound | Class | Primary mechanism | Commonly reported for | Link |
|---|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | Upregulates growth factor receptors; promotes angiogenesis and collagen synthesis | Tendon, ligament, muscle, and gut repair | View profile → |
| TB-500 | Thymosin Beta-4 analogue | Actin sequestration; promotes cell migration, angiogenesis, and tissue remodelling | Systemic healing, muscle injury, WADA-listed | View profile → |
| GHK-Cu | Copper peptide | Activates collagen and elastin synthesis; anti-inflammatory; wound healing | Skin regeneration, tissue repair, anti-aging | View profile → |
| KPV | α-MSH tripeptide | MC1R/MC3R agonism; anti-inflammatory; reported oral activity | Inflammation, gut healing, wound healing | View profile → |
Tissue repair is a multi-phase process involving haemostasis, inflammation, proliferation, and remodelling. The proliferative phase — during which new tissue is actively laid down — depends on four interconnected processes: angiogenesis (the formation of new blood vessels to supply the repair zone), collagen synthesis (the deposition of extracellular matrix scaffolding), cell migration (the movement of fibroblasts, endothelial cells, and progenitor cells to the injury site), and growth factor upregulation (particularly VEGF, TGF-β, EGF, and FGF). Research has investigated peptides for their potential role in modulating each of these processes individually and in combination. The relative contribution of each mechanism differs by tissue type — tendons and ligaments are predominantly collagen-dependent, muscle repair relies heavily on satellite cell migration and myogenesis, and wound healing in skin involves all four processes in sequence.
BPC-157 is a 15-amino acid peptide derived from a sequence found in human gastric juice, and research has investigated it for its potential role in a broad range of tissue repair contexts. Proposed mechanisms include upregulation of growth factor receptors — particularly VEGFR2 and EGFR — which may amplify endogenous repair signalling, and modulation of the nitric oxide (NO) system, which is implicated in vasodilation and angiogenesis at injury sites. Research has additionally investigated BPC-157 for its potential role in VEGF pathway activation, with preclinical data suggesting increased vascular density in injured tissue following administration. These convergent mechanisms are proposed to explain the compound's apparent breadth of effect across tendons, ligaments, muscle, and gastrointestinal tissue in animal models, though human controlled trial data remain limited.
Thymosin Beta-4 — and its synthetic research analogue TB-500 — operates through a fundamentally different mechanism centred on actin dynamics. Thymosin Beta-4 sequesters G-actin (monomeric actin), the building block of the actin cytoskeleton, which reduces actin polymerisation at the cell membrane and thereby increases the pool of free actin available for cytoskeletal rearrangement. This promotes cell motility, enabling fibroblasts, endothelial cells, and other repair-relevant cell types to migrate into damaged tissue more effectively. Thymosin Beta-4 additionally promotes angiogenesis and has been investigated for its role in activating cardiac and skeletal muscle progenitor cells. A key distinction from BPC-157 is that Thymosin Beta-4 is proposed to act more systemically — distributing to sites of damage throughout the body rather than exerting primarily local effects — a characteristic that makes it of interest in research involving diffuse or multi-site injury. TB-500 is listed on the WADA prohibited substances list, which is a relevant consideration for any research involving competitive athletes.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein sequence identified in human gastric mucosa. Research has investigated BPC-157 for its potential role in tendon-to-bone healing, ligament repair, muscle injury recovery, and gastrointestinal mucosal protection, with a substantial preclinical literature in rodent models across all these contexts. Proposed mechanisms include upregulation of VEGFR2 and nitric oxide synthase activity, which are implicated in angiogenesis and blood flow to repair sites. Commonly reported doses range from 250 mcg to 500 mcg per administration, delivered subcutaneously or intraperitoneally in research settings. Anecdotal reports suggest improvement in injury recovery timelines, and the compound has also been explored in oral form for gastrointestinal applications, though the bioavailability of systemic effects via oral administration is a subject of ongoing discussion in the research community.
TB-500 is a synthetic analogue of Thymosin Beta-4 corresponding to the actin-binding region of the full protein. Research has investigated TB-500 for its potential role in promoting cell migration, angiogenesis, and tissue remodelling following musculoskeletal injury, with preclinical data suggesting accelerated healing in muscle tear and tendon injury models. Its proposed mechanism — sequestration of G-actin to enhance cell motility — is systemic in nature, distinguishing it from compounds with primarily local action. Commonly reported doses in research protocols range from 2 mg to 5 mg per week, typically administered subcutaneously over 4 to 6 weeks. TB-500 is listed as a prohibited substance by WADA, and this status is a material consideration for any research involving competitive athletes subject to anti-doping regulations.
GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) that exists endogenously in human plasma and declines with age. Research has investigated GHK-Cu for its potential role in activating collagen and elastin synthesis, reducing matrix metalloproteinase activity, and promoting wound healing through anti-inflammatory signalling. The copper ion in the complex is proposed to participate directly in enzymatic processes involved in connective tissue synthesis, including lysyl oxidase activity required for collagen crosslinking. Commonly reported research applications include topical formulations for skin repair and systemic administration for connective tissue contexts, with doses varying significantly by route. Anecdotal reports suggest improvement in skin texture and wound closure rates, and it is frequently included in healing stacks for its collagen-specific mechanism.
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH), retaining the parent molecule's anti-inflammatory activity while being significantly smaller. Research has investigated KPV for its potential role in reducing inflammatory cytokine production via MC1R and MC3R melanocortin receptor agonism, with reported activity in gut mucosal inflammation, skin wound healing, and systemic inflammatory contexts. A distinctive feature of interest in research is KPV's reported oral activity — studies have investigated its ability to reach gut tissue following oral administration and exert local anti-inflammatory effects, making it of particular relevance in gastrointestinal healing research. Commonly reported doses range from 500 mcg to 1 mg per administration. Anecdotal reports suggest improvement in inflammatory symptoms and gut discomfort, particularly in contexts involving colitis or mucosal irritation.
Wolverine (BPC-157 + TB-500) →
The most commonly reported healing stack in peptide research contexts. BPC-157 provides localised growth factor upregulation and angiogenesis at injury sites, while TB-500 contributes systemic cell migration and tissue remodelling via the actin-sequestration pathway. The two mechanisms are proposed to be complementary rather than redundant — BPC-157 anchoring the repair response locally and TB-500 recruiting repair-competent cells from the broader systemic pool. Anecdotal reports suggest improvement in recovery timelines for tendon, ligament, and muscle injuries when the two are used concurrently.
GLOW (BPC-157 + TB-500 + GHK-Cu) →
An extension of the Wolverine stack with the addition of GHK-Cu, targeting connective tissue repair with a specific emphasis on collagen and elastin synthesis. GHK-Cu's collagen-activating mechanism adds a third complementary pathway — structural matrix deposition — alongside BPC-157's vascular and growth factor effects and TB-500's cell migration activity. This combination has been reported in anecdotal research contexts focused on skin quality, wound healing, and connective tissue integrity alongside musculoskeletal repair.
KLOW (BPC-157 + TB-500 + GHK-Cu + KPV) →
The full quad-compound recovery stack, adding KPV to the GLOW combination for its anti-inflammatory contribution via melanocortin receptor agonism. KPV is proposed to address the inflammatory component of healing — particularly relevant in chronic overuse injury, gut mucosal involvement, or cases where systemic inflammation may be impeding the repair process. Research has investigated each component independently; the combination represents a rationale-driven approach to covering multiple phases and pathways of the healing response simultaneously.
What is the difference between BPC-157 and TB-500, and why are they often combined?
BPC-157 and TB-500 differ in both mechanism and distribution. BPC-157 is proposed to act primarily at the site of administration through VEGF and nitric oxide pathway modulation, driving local angiogenesis and growth factor receptor upregulation. TB-500 acts systemically through actin sequestration, increasing the motility of repair-competent cells throughout the body. The rationale for combining them is that BPC-157 creates a favourable repair environment locally while TB-500 enhances the body's ability to recruit and mobilise cells to that site from a distance. The two mechanisms are not redundant, which is why their combination is the most documented pairing in healing-focused research contexts.
Does subcutaneous BPC-157 produce different effects than oral BPC-157 for healing?
Research has investigated both routes in different contexts. Subcutaneous injection is proposed to produce systemic availability and is the predominant route used in musculoskeletal injury research, with administration near the injury site sometimes reported anecdotally as producing more localised effects. Oral BPC-157 has been specifically investigated for gastrointestinal mucosal applications — the peptide was originally derived from gastric juice and appears to maintain activity within the GI tract when administered orally. Whether orally-administered BPC-157 reaches systemic circulation at therapeutically relevant concentrations for non-GI tissues remains a subject of research discussion, with bioavailability data being limited compared to injectable routes.
What is GHK-Cu's specific role in collagen and skin healing research?
GHK-Cu has been investigated for its potential role in directly upregulating collagen synthesis at the gene expression level, with research suggesting activation of collagen type I and III production in fibroblasts. The copper component is proposed to support lysyl oxidase activity — an enzyme essential for collagen and elastin crosslinking, which determines the structural integrity of the extracellular matrix. Research has also investigated GHK-Cu for its anti-inflammatory properties and its potential to downregulate matrix metalloproteinases (MMPs) that degrade existing collagen. In skin healing contexts specifically, these combined effects — more collagen produced, better crosslinked, and less degraded — make it of particular research interest for wound repair, scar remodelling, and age-related connective tissue decline.
Why is KPV's oral route significant in gut healing research?
Most peptides are degraded by gastric proteases before reaching the intestinal mucosa in meaningful concentrations, limiting their utility for gut-targeted applications via oral administration. KPV is a tripeptide of only three amino acids, and its small size and structural properties appear to confer relative resistance to gastrointestinal degradation. Research has investigated KPV's oral route for its potential role in reaching colonic mucosa and exerting anti-inflammatory effects via MC1R/MC3R melanocortin receptors locally in gut tissue, with preclinical data suggesting activity in colitis models. This oral route is directly relevant to its proposed application in gut healing research, where systemic injection would be a suboptimal delivery mechanism for a locally-acting mucosal target.